30 completed, 5 terminated, 4 withdrawn, 1 recruiting. 21 Phase 1, 20 Phase 2, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 15, Terminated 4, Withdrawn 2 |
| Phase 2 | 20 | Completed 18, Withdrawn 2 |
| Not applicable | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Recurrent Squamous Cell Carcinoma of the Hypopharynx: new trials by email Literature Review of Recurrent Squamous Cell Carcinoma of the Hypopharynx trials Research Report on Recurrent Squamous Cell Carcinoma of the Hypopharynx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck sorafenib tosylate, cisplatin, docetaxel - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 3 | 2014-04-14 | 2018-05-24 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy entolimod, intensity-modulated radiation therapy, cisplatin - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2014-01-01 | 2013-12-11 | |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy placebo, quality-of-life assessment, questionnaire administration - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-05-01 | 2013-05-15 | |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | University of Chicago | 48 | 2013-03-26 | 2024-07-31 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer transoral robotic surgery, laboratory biomarker analysis, quality-of-life assessment - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Lymphoepithelioma of the Nasopharynx | Not applicable | Terminated | City of Hope Medical Center | 7 | 2011-04-01 | 2014-11-10 |
| Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy everolimus, erlotinib hydrochloride, biopsy - Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2011-04-01 | 2023-04-04 | |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer quality-of-life assessment, management of therapy complications, L-lysine - Mucositis, Oral Complications of Chemotherapy | Not applicable | Completed | University of Washington | 10 | 2010-09-01 | 2013-05-17 |
| Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck lapatinib ditosylate, capecitabine - Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 44 | 2009-10-01 | 2020-03-19 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck transoral robotic surgery, quality of life assessment - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 600 | 2007-12-03 | 2026-02-10 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer saracatinib, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2007-07-01 | 2014-04-30 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer dasatinib, pharmacological study, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2007-07-01 | 2014-10-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
Showing 20 of 40. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (40) · Salivary Gland Neoplasms (29) · Tongue Neoplasms (21) · Esthesioneuroblastoma, Olfactory (10) · Carcinoma, Non-Small-Cell Lung (8) · Colonic Neoplasms (6) · Carcinoma, Ovarian Epithelial (5) · Anus Neoplasms (4) · Breast Neoplasms (4) · Esophageal Neoplasms (4) · Pancreatic Neoplasms (4) · Rectal Neoplasms (4) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Mucositis (3)
Carcinoma (40) · Neoplasms by Histologic Type (40) · Neoplasms by Site (40) · Neoplasms, Glandular and Epithelial (40) · Carcinoma, Squamous Cell (39) · Head and Neck Neoplasms (39) · Neoplasms (39) · Mouth Diseases (34) · Stomatognathic Diseases (34) · Mouth Neoplasms (33) · Salivary Gland Diseases (29) · Tongue Diseases (21) · Cranial Nerve Diseases (10) · Digestive System Diseases (10) · Gastrointestinal Diseases (10)
Cetuximab (8) · Erlotinib Hydrochloride (8) · Bevacizumab (4) · Carboplatin (3) · Lapatinib (3) · Sorafenib (3) · Taxes (3) · Capecitabine (2) · Cisplatin (2) · Docetaxel (2) · Everolimus (2) · Fluorouracil (2) · Hydroxyurea (2) · Irinotecan (2) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (2)
National Cancer Institute (NCI) (23) · Fox Chase Cancer Center (3) · Roswell Park Cancer Institute (3) · Ohio State University Comprehensive Cancer Center (2) · University of Chicago (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · Abramson Cancer Center at Penn Medicine (1) · City of Hope Medical Center (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (36) · Canada (1)
Anurag Singh (2) · Barbara Burtness (2) · Ezra Cohen (2) · Jill Gilbert (2) · Tanguy Seiwert (2) · Alain Mita (1) · Antonius Miller (1) · Charles Rudin (1) · Christopher Thomas (1) · Corey Langer (1) · David Gustin (1) · David Schwartz, MD (1) · David Solit (1) · Ellie Maghami (1) · Enver Ozer, MD (1)
PMID 19201650, PMID 23868427, PMID 25057165, PMID 26928328, PMID 35429391, PMID 35945244, PMID 40166973
N01CM62201 (4), U10CA032102 (3), N01CM62202 (2), P30CA014599 (2), P30CA016672 (2), U10CA021115 (2), N01CM00100 (1), N01CM17102 (1), N01CM62203 (1), N01CM62206 (1), N01CM62209 (1), P30CA006927 (1), P30CA015704 (1), P30CA044579 (1), P30CA054174 (1)